Biotech entity

Insilico Medicine

Company

Of the tracked stories, 3 of 3 also mention Pharma.AI, the most common co-covered peer. The clearest coverage concentration is pharma: 2 of 3 stories, with the rest divided among 1 other category. Source depth averages 2.7 original sources per story, versus 3.8 across the same-window beat baseline.

Last mentioned: Jul 15, 2026

Entity pulse

Recent coverage · Insilico Medicine

3 stories
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Insilico Medicine

Of the tracked stories, 3 of 3 also mention Pharma.AI, the most common co-covered peer. The clearest coverage concentration is pharma: 2 of 3 stories, with the rest divided among 1 other category. Source depth averages 2.7 original sources per story, versus 3.8 across the same-window beat baseline. That works out to roughly 0.2 stories per week across a 132-day span. Their average consequence score of 7 runs above the beat's 6.3 for that window. We currently track 3 Biotech stories that mention Insilico Medicine, published between March 6, 2026 and July 15, 2026.

Stories tracked
3
Per week
0.2
Sources per story
2.7

Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 395 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Insilico Medicine. Shared-story counts are live from our verified record — not editorial picks.

Key Data

ticker
3696
name
Insilico Medicine
price
null
change
null
changePct
null

Timeline

  1. Phase I Initiation

    First human subject enrolled and dosed in the Phase I clinical trial.

  2. Out-Licensing Deal

    TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.

  3. Candidate Discovery

    Insilico Medicine identifies ISM4808 using generative AI models.

Stories mentioning Insilico Medicine 3

Pharma Positive

Multi-Target AI Alliance Targets $2.5B Potential to Redraw Pharma R&D Model

The proposed alliance between AI powerhouse Insilico Medicine and CDMO Bora Pharmaceuticals could create a seamless pipeline from generative chemistry to commercial manufacturing. With a headline potential of over $2.5 billion, the deal targets multiple therapeutic programs and directly addresses the translational gap that often stalls promising drug candidates.

3 sources

Source: prnewswire.com · prnewswire.com

Pharma Strongly positive

Insilico's $2.5B AI CNS Biobucks Deal With SK Bio Sets APAC Record

In the largest Asia‑Pacific licensing deal for Insilico Medicine, the AI‑first biotech secured up to $2.5 billion in milestones plus royalties from South Korea's SK Biopharmaceuticals, a CNS powerhouse, to co‑develop next‑generation neuroimmune therapies. The heavily back‑ended structure reflects industry‑standard risk‑sharing, with Insilico taking $18M up front and SK steering commercialization, underscoring a growing appetite for AI‑discovered assets in big pharma pipelines.

2 sources
Clinical Trials Positive

Insilico and TaiGen Advance AI-Derived CKD Anemia Candidate to Phase I

Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.

3 sources

Insilico Medicine is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.